As of May 2026, peptide-related hashtags had topped 130,000 Instagram posts and 230 million TikTok views — and according to a new JAMA Viewpoint, the regulatory frameworks meant to govern these compounds are struggling to keep pace.
Piatkowski, Ganson, and Nagata argue that injectable peptides such as body protective compound -157, increasingly promoted online for muscle growth, recovery, and antiaging, are no longer circulating solely through conventional pharmaceutical channels. Instead, they move simultaneously through FDA-approved therapeutic markets, legal compounding frameworks, and unregulated illicit channels, blurring the line between medicine and enhancement. The evidence base is thin: mechanistic concerns raise potential risks such as pathologic angiogenesis and toxic metabolites, while human data remain limited. Awareness, the authors note, appears higher among younger populations, particularly adolescent boys and young men exposed to social media–driven body ideals.
A central argument of the Viewpoint is that the problem is not a lack of regulatory tools but rather their fragmentation across regulatory, digital, and clinical systems. The FDA has restricted several peptides from compounding even as policy discussions tied to Robert F. Kennedy Jr's Make America Healthy Again platform have floated loosening access. The authors argue that this instability does not eliminate demand. As they put it, "such instability does not eliminate demand but may displace use toward unregulated supply channels."
They argue that the friction is structural. The digital ecosystems driving uptake — including influencer content, biohacking narratives, and direct-to-consumer supply — sit largely outside traditional regulatory oversight, leaving conventional enforcement reactive rather than preventive. Compounding the challenge, research on illicit peptide use remains sparse, despite the relative ease of studying these compounds.
The authors contend that peptides occupy a uniquely difficult regulatory position because some peptide-based therapies—including glucagon-like peptide-1 receptor agonists such as semaglutide and tirzepatide—are widely accepted medical treatments, while other peptides are marketed online for enhancement purposes. That overlap, they argue, makes conventional distinctions between therapeutic and enhancement drug use increasingly difficult to maintain.
The clinical implication is that many people using peptides for enhancement may not view the behavior as substance use at all. If so, clinicians may be among the few positioned to identify exposures and emerging harms that existing surveillance systems are not built to capture. The authors conclude that without more adaptive, system-oriented responses, drug policy will remain reactive and insufficient to address the evolving peptide marketplace.
Disclosures can be found in the original Viewpoint.
Source: JAMA
